116 related articles for article (PubMed ID: 27826831)
1. Phase 1b study of orteronel in postmenopausal women with hormone-receptor positive (HR+) metastatic breast cancer.
Rampurwala M; Wisinski KB; Burkard ME; Ehsani S; O'Regan RM; Carmichael L; Kim K; Kolesar J; Tevaarwerk AJ
Invest New Drugs; 2017 Feb; 35(1):87-94. PubMed ID: 27826831
[TBL] [Abstract][Full Text] [Related]
2. Phase 1/2 study of orteronel (TAK-700), an investigational 17,20-lyase inhibitor, with docetaxel-prednisone in metastatic castration-resistant prostate cancer.
Petrylak DP; Gandhi JG; Clark WR; Heath E; Lin J; Oh WK; Agus DB; Carthon B; Moran S; Kong N; Suri A; Bargfrede M; Liu G
Invest New Drugs; 2015 Apr; 33(2):397-408. PubMed ID: 25556680
[TBL] [Abstract][Full Text] [Related]
3. Phase I/II trial of orteronel (TAK-700)--an investigational 17,20-lyase inhibitor--in patients with metastatic castration-resistant prostate cancer.
Dreicer R; MacLean D; Suri A; Stadler WM; Shevrin D; Hart L; MacVicar GR; Hamid O; Hainsworth J; Gross ME; Shi Y; Webb IJ; Agus DB
Clin Cancer Res; 2014 Mar; 20(5):1335-44. PubMed ID: 24418642
[TBL] [Abstract][Full Text] [Related]
4. Effect of an investigational CYP17A1 inhibitor, orteronel (TAK-700), on estrogen- and corticoid-synthesis pathways in hypophysectomized female rats and on the serum estradiol levels in female cynomolgus monkeys.
Yamaoka M; Hara T; Araki H; Kaku T; Hitaka T; Tasaka A; Kusaka M
J Steroid Biochem Mol Biol; 2013 Nov; 138():298-306. PubMed ID: 23856460
[TBL] [Abstract][Full Text] [Related]
5. A Phase II Study Evaluating Orteronel, an Inhibitor of Androgen Biosynthesis, in Patients With Androgen Receptor (AR)-Expressing Metastatic Breast Cancer (MBC).
Yardley DA; Young RR; Adelson KB; Silber AL; Najera JE; Daniel DB; Peacock N; Finney L; Hoekstra SJ; Shastry M; Hainsworth JD; Burris HA
Clin Breast Cancer; 2022 Apr; 22(3):269-278. PubMed ID: 34824002
[TBL] [Abstract][Full Text] [Related]
6. Orteronel (TAK-700), a novel non-steroidal 17,20-lyase inhibitor: effects on steroid synthesis in human and monkey adrenal cells and serum steroid levels in cynomolgus monkeys.
Yamaoka M; Hara T; Hitaka T; Kaku T; Takeuchi T; Takahashi J; Asahi S; Miki H; Tasaka A; Kusaka M
J Steroid Biochem Mol Biol; 2012 Apr; 129(3-5):115-28. PubMed ID: 22249003
[TBL] [Abstract][Full Text] [Related]
7. A phase 1 multiple-dose study of orteronel in Japanese patients with castration-resistant prostate cancer.
Suzuki K; Ozono S; Yamaguchi A; Koike H; Matsui H; Nagata M; Takubo T; Miyashita K; Matsushima T; Akaza H
Cancer Chemother Pharmacol; 2015 Feb; 75(2):373-80. PubMed ID: 25537627
[TBL] [Abstract][Full Text] [Related]
8. Effect of a novel 17,20-lyase inhibitor, orteronel (TAK-700), on androgen synthesis in male rats.
Hara T; Kouno J; Kaku T; Takeuchi T; Kusaka M; Tasaka A; Yamaoka M
J Steroid Biochem Mol Biol; 2013 Mar; 134():80-91. PubMed ID: 23146910
[TBL] [Abstract][Full Text] [Related]
9. Orteronel for the treatment of prostate cancer.
Van Hook K; Huang T; Alumkal JJ
Future Oncol; 2014 Apr; 10(5):803-11. PubMed ID: 24799061
[TBL] [Abstract][Full Text] [Related]
10. Phase II study of single-agent orteronel (TAK-700) in patients with nonmetastatic castration-resistant prostate cancer and rising prostate-specific antigen.
Hussain M; Corn PG; Michaelson MD; Hammers HJ; Alumkal JJ; Ryan CJ; Bruce JY; Moran S; Lee SY; Lin HM; George DJ;
Clin Cancer Res; 2014 Aug; 20(16):4218-27. PubMed ID: 24965748
[TBL] [Abstract][Full Text] [Related]
11. Phase 1 study of seviteronel, a selective CYP17 lyase and androgen receptor inhibitor, in women with estrogen receptor-positive or triple-negative breast cancer.
Bardia A; Gucalp A; DaCosta N; Gabrail N; Danso M; Ali H; Blackwell KL; Carey LA; Eisner JR; Baskin-Bey ES; Traina TA
Breast Cancer Res Treat; 2018 Aug; 171(1):111-120. PubMed ID: 29744674
[TBL] [Abstract][Full Text] [Related]
12. Orteronel plus prednisone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (ELM-PC 4): a double-blind, multicentre, phase 3, randomised, placebo-controlled trial.
Saad F; Fizazi K; Jinga V; Efstathiou E; Fong PC; Hart LL; Jones R; McDermott R; Wirth M; Suzuki K; MacLean DB; Wang L; Akaza H; Nelson J; Scher HI; Dreicer R; Webb IJ; de Wit R;
Lancet Oncol; 2015 Mar; 16(3):338-48. PubMed ID: 25701170
[TBL] [Abstract][Full Text] [Related]
13. Targeting the adrenal gland in castration-resistant prostate cancer: a case for orteronel, a selective CYP-17 17,20-lyase inhibitor.
Zhu H; Garcia JA
Curr Oncol Rep; 2013 Apr; 15(2):105-12. PubMed ID: 23371447
[TBL] [Abstract][Full Text] [Related]
14. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer.
Johnston S; Pippen J; Pivot X; Lichinitser M; Sadeghi S; Dieras V; Gomez HL; Romieu G; Manikhas A; Kennedy MJ; Press MF; Maltzman J; Florance A; O'Rourke L; Oliva C; Stein S; Pegram M
J Clin Oncol; 2009 Nov; 27(33):5538-46. PubMed ID: 19786658
[TBL] [Abstract][Full Text] [Related]
15. Adjuvant endocrine therapy in pre- versus postmenopausal patients with steroid hormone receptor-positive breast cancer: results from a large population-based cohort of a cancer registry.
Inwald EC; Koller M; Klinkhammer-Schalke M; Zeman F; Hofstädter F; Lindberg P; Gerstenhauer M; Schüler S; Treeck O; Ortmann O
J Cancer Res Clin Oncol; 2015 Dec; 141(12):2229-40. PubMed ID: 26253629
[TBL] [Abstract][Full Text] [Related]
16. Phase II, randomized trial to compare anastrozole combined with gefitinib or placebo in postmenopausal women with hormone receptor-positive metastatic breast cancer.
Cristofanilli M; Valero V; Mangalik A; Royce M; Rabinowitz I; Arena FP; Kroener JF; Curcio E; Watkins C; Bacus S; Cora EM; Anderson E; Magill PJ
Clin Cancer Res; 2010 Mar; 16(6):1904-14. PubMed ID: 20215537
[TBL] [Abstract][Full Text] [Related]
17. Orteronel for Metastatic Hormone-Sensitive Prostate Cancer: A Multicenter, Randomized, Open-Label Phase III Trial (SWOG-1216).
Agarwal N; Tangen CM; Hussain MHA; Gupta S; Plets M; Lara PN; Harzstark AL; Twardowski PW; Paller CJ; Zylla D; Zibelman MR; Levine E; Roth BJ; Goldkorn A; Vaena DA; Kohli M; Crispino T; Vogelzang NJ; Thompson IM; Quinn DI
J Clin Oncol; 2022 Oct; 40(28):3301-3309. PubMed ID: 35446628
[TBL] [Abstract][Full Text] [Related]
18. Is still there a place for orteronel in management of prostate cancer? Data from a literature based meta-analysis of randomized trials.
Roviello G; Pacifico C; Chiriacò G; Generali D
Crit Rev Oncol Hematol; 2017 May; 113():18-21. PubMed ID: 28427507
[TBL] [Abstract][Full Text] [Related]
19. Biomarker Associations with Efficacy of Abiraterone Acetate and Exemestane in Postmenopausal Patients with Estrogen Receptor-Positive Metastatic Breast Cancer.
Li W; O'Shaughnessy J; Hayes D; Campone M; Bondarenko I; Zbarskaya I; Brain E; Stenina M; Ivanova O; Graas MP; Neven P; Ricci D; Griffin T; Kheoh T; Yu M; Gormley M; Martin J; Schaffer M; Zelinsky K; De Porre P; Johnston SR
Clin Cancer Res; 2016 Dec; 22(24):6002-6009. PubMed ID: 27267854
[TBL] [Abstract][Full Text] [Related]
20. Phase II study of vorozole (R83842), a new aromatase inhibitor, in postmenopausal women with advanced breast cancer in progression on tamoxifen.
Goss PE; Clark RM; Ambus U; Weizel HA; Wadden NA; Crump M; Walde D; Tye LM; De Coster R; Bruynseels J
Clin Cancer Res; 1995 Mar; 1(3):287-94. PubMed ID: 9815984
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
